Table 1 Characteristics of study population at baseline
From: Inflammation-associated microRNA changes in circulating exosomes of heart failure patients
| Â | Cases | Controls | Overall | p value |
|---|---|---|---|---|
Number | 40 | 20 | 60 | Â |
Age—year (SD) | 66.5 (10.5) | 60.6 (15.7) | 64.5 (12.6) | 0.09 |
Sex—no. (%) |  |  |  | 0.16 |
 Male | 40/40 (100%) | 19/20 (95%) | 59/60 (98%) |  |
Race—no. (%) | ||||
 White | 31/40 (78%) | 16/20 (80%) | 47/60 (80%) | 0.82 |
 African American | 9/40 (22%) | 3/20 (15%) | 3/20 (15%) | 0.50 |
 Others |  | 1/20 (5%) | 1/20 (5%) | 0.16 |
Body mass index (SD) | 30.4 (7.4) | 28.8 (6.1) | 29.9 (7.0) | 0.40 |
Medical history—no. (%) | ||||
 Hypertension | 32/40 (80%) | 11/20 (55%) | 43/60 (72%) | 0.04 |
 Type 2 diabetes | 23/40 (58%) | 3/20 (15%) | 26/60 (43%) | 0.01 |
 Coronary artery disease | 23/40 (58%) | 2/20 (10%) | 25/60 (42%) | 0.00 |
 Chronic kidney disease | 21/40 (53%) | 1/20 (5%) | 22/60 (37%) | 0.00 |
 Alcohol abuse | 3/40 (8%) | 1/20 (5%) | 4/60 (7%) | 0.72 |
 Drug use | 3/40 (8%) | 2/20 (10%) | 5/60 (8%) | 0.74 |
Medications—no. (%) | ||||
 Aspirin | 34/40 (85%) | 6/20 (30%) | 40/60 (67%) | 0.00 |
 Beta-blocker | 38/40 (95%) | 7/20 (35%) | 45/60 (75%) | 0.00 |
 ACE/ARB | 35/40 (88%) | 2/20 (10%) | 37/60 (62%) | 0.00 |
 Spirinolactone | 16/40 (40%) | 0/20 (0%) | 16/60 (27%) | 0.00 |
 Statin | 34/40 (85%) | 9/20 (45%) | 43/60 (72%) | 0.00 |